Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

axichem pty ltd - glufosinate-ammonium - soluble concentrate - glufosinate-ammonium organophosphorus-phosphinic ac active 200.0 g/l - herbicide - avocado plantation | banana plantation | blackberry | boysenberry | cane berry fruit | citrus fruit orchard | commercial area - - amaranth or amaranthus | annual or wimmera ryegrass | apple-of-peru | argentine peppercress | awnless barnyard grass | barley grass | barnyard grass or water grass | billygoat weed or blue top | bindweed | black bindweed | bladder ketmia | blady grass | bordered panic | brome grass | calopo | caltrop or yellow vine | cape tulip | capeweed | centro | clammy goosefoot | clover glycine | cobbler's pegs | common bittercress or flickweed | common fumitory | common storksbill | couch grass | cowpea | crowsfoot grass | deadnettle | fat hen | foxtail millet | green crumbweed | greenleaf desmodium | indian hedge mustard | johnson grass | lesser canary grass | liverseed or urochloa grass | medic | mimosa invisa | mintweed | new zealand spinach | panic | paspalum spp. | paterson's curse | perennial pigweed | pigweed spp. | pink shamrock | pinkburr | pinus spp. - regeneration | potato or yellow weed | prairie or annual prairie grass | prickly lettuce | primocane control | red natal grass | saffron thistle | sago weed | s

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - ambrisentan, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; lecithin - cipla ambrisentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary artrial hypertension associated with connective tissue disease (pah-ctd),,in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - ambrisentan, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; lecithin - cipla ambrisentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary artrial hypertension associated with connective tissue disease (pah-ctd),,in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - ambrisentan, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; lecithin - ambrisentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary artrial hypertension associated with connective tissue disease (pah-ctd),,in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - ambrisentan, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; lecithin - ambrisentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary artrial hypertension associated with connective tissue disease (pah-ctd),,in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - bosentan monohydrate, quantity: 129.082 mg - tablet, film coated - excipient ingredients: maize starch; pregelatinised maize starch; sodium starch glycollate type a; povidone; glycerol dibehenate; magnesium stearate; hypromellose; titanium dioxide; triacetin; purified talc; iron oxide yellow; iron oxide red; ethylcellulose; cetyl alcohol; sodium lauryl sulfate - for the treatment of ? idiopathic pulmonary arterial hypertension ? familial pulmonary arterial hypertension ? pulmonary arterial hypertension associated with scleroderma or ? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - bosentan monohydrate, quantity: 64.541 mg - tablet, film coated - excipient ingredients: maize starch; pregelatinised maize starch; sodium starch glycollate type a; povidone; glycerol dibehenate; magnesium stearate; hypromellose; titanium dioxide; triacetin; purified talc; iron oxide yellow; iron oxide red; ethylcellulose; cetyl alcohol; sodium lauryl sulfate - for the treatment of ? idiopathic pulmonary arterial hypertension ? familial pulmonary arterial hypertension ? pulmonary arterial hypertension associated with scleroderma or ? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - bosentan monohydrate, quantity: 64.541 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate type a; glycerol dibehenate; magnesium stearate; povidone; maize starch; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - bosentan is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - bosentan monohydrate, quantity: 64.541 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; glycerol dibehenate; maize starch; sodium starch glycollate type a; magnesium stearate; povidone; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - bosentan is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - bosentan monohydrate, quantity: 129.083 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; glycerol dibehenate; povidone; maize starch; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - bosentan is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms